CMS begins clinical rollout of Silevimig, first bispecific antibody for rabies passive immunisation
China Medical System Holdings (CMS) has begun the clinical rollout of Silevimig, the world's first bispecific antibody for rabies passive immunisation. Initial prescriptions were issued at multiple hospitals in China. Silevimig is a Class 1 innovative drug with a smaller dose and lower injection volume compared to human rabies immune globulin (HRIG). It was approved in China in June 2026 and is manufactured using recombinant technology, eliminating the risk of blood-borne infections. CMS aims to
How this was made
The 30-second read
Why it matters
The article frames the milestone as a transition from regulatory approval to clinically accessible treatment, citing Phase III adult efficacy and an ongoing pediatric trial.
Market read
Traders can treat this as a commercialization traction signal for CMS’s rabies franchise, with follow-through dependent on prescription scale and payer/access economics.
What to watch
Key swing factors are actual prescription volumes, pricing versus HRIG, distribution capacity, and outcomes from the ongoing pediatric Phase III trial that could affect label expansion and adoption.
Background
Silevimig is described as the first fully human bispecific antibody for rabies passive immunisation, designed to provide immediate protection while vaccination-induced immunity develops.
Ticker impact
China Medical System Holdings says initial prescriptions for Silevimig have been issued at multiple hospitals, starting large-scale clinical rollout after June 2026 approval.
Mild-to-moderate positive bias for CMS shares as investors price earlier-than-expected commercialization traction, though magnitude depends on subsequent prescription volumes and payer coverage.
The article provides a specific, time-linked commercialization step (initial prescriptions across named hospitals) plus prior Phase III efficacy and June 2026 approval, which together reduce uncertainty versus a purely regulatory or trial-stage update.
Market effects
Supports the infectious-disease passive immunization theme in China, potentially increasing competitive pressure on HRIG supply and pricing dynamics.
China rabies post-exposure care market could shift toward non-plasma, recombinant products if access and cost barriers fall.
If Silevimig scales in China, it strengthens the case for broader Asia-Pacific commercialization under the existing licensing structure.
Counterpoint
Initial prescriptions at a handful of hospitals may not translate into sustained demand if reimbursement remains limited or if clinicians continue to default to HRIG.
Key entities
- companyChina Medical System Holdings
Announced initial prescriptions for Silevimig across multiple hospitals, marking the start of large-scale clinical application in China.
- productSilevimig Injection
Bispecific antibody for rabies passive immunisation, approved for marketing in China in June 2026.
- partnerGenrix Bio
Partner under an exclusive collaboration agreement for commercialisation rights and development support.
